Rapidly worsening hypertriglyceridemia during treatment with risperidone

American Journal of Therapeutics

Volumn 17, Issue 2, 2010, Pages 216-218

  Kohen, Izchak ^a,b   Manu, Peter ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Antipsychotics; Hypertriglyceridemia; Metabolic syndrome

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; RISPERIDONE; TRIACYLGLYCEROL;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTRIGLYCERIDEMIA; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; OBESITY, MORBID; RISK FACTORS; RISPERIDONE; SCHIZOPHRENIA; TIME FACTORS;

EID: 77949953966     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318197eadf     Document Type: Article

References (12)

1. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol. 2001;21:369-374.
2. Zipes DP. Braunwald,s Heart Disease: A Textbook of Cardiovascular Medicine. 7th ed. Philadelphia, PA: Suanders; 2005.
3. Grundy SM, Brewer HB, Cleeman JI, et al. Definition of metabolic syndrome. Circulation. 2004;109:433-438.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
5. Nagamine T. Olanzapine-induced elevation of serum triglycerides levels in a normal weight patient with schizophrenia. Intern Med. 2008;47:181-182.
6. Osser DN, Najaren DM, Dufresne RL. Olanzapine increased weight and serum triglycerides levels. J Clin Psychiatry. 1999;60:767-770.
7. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70:1-17.
8. Baptista T, Lacruz A, Angeles F, et al. Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry. 2001;34:223-231.
9. Markham-Abedi C, de Leon J. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report. J Clin Psychiatry. 2006;67: 1473-1474.
10. Procyshyn RM, Wasan KM, Thornton AE, et al. Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci. 2007;32:331-338.
11. Yamamoto K, Fukuda M, Nogawa A, et al. Decreased lipoprotein lipase as a risk factor for atypical neurolepticinduced hypertriglyceridemia. J Clin Psychiatry. 2007; 68:802.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.